Effects of bisphosphonate (pamidronate) on bone resorption resulting from metastasis of a squamous cell carcinoma: Report of an autopsy case and evaluation of bone resorbing activity in an experimental animal model

Journal of Oral and Maxillofacial Surgery

Volumn 54, Issue 11, 1996, Pages 1327-1333

  Hiraga, Tooru ^a,b   Takada, Masahito ^a,b   Nakajima, Tamio ^a,b   Ozawa, Hidehiro ^a,c  

^a NIIGATA UNIVERSITY   (Japan)

^b First Dept Oral Maxillofacial Surg   (Japan)

^c First Department of Oral Anatomy

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID;

AGED; ARTICLE; AUTOPSY; BONE METASTASIS; CASE REPORT; CELL POLARITY; CELL ULTRASTRUCTURE; DRUG EFFECT; FEMALE; HUMAN; HYPERCALCEMIA; OSTEOCLAST; OSTEOLYSIS; SQUAMOUS CELL CARCINOMA; STEM CELL;

EID: 0030453805     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-2391(96)90492-9     Document Type: Article

References (29)

1. Mundy GR: Incidence and pathophysiology of hypercalcemia. Calcif Tissue Int 46:S3, 1990
2. Won C, Decker DA, Drelichman A, et al: Hypercalcemia in head and neck carcinoma: Incidence and prognosis. Cancer 52:2261, 1983
3. Yoneda T, Nishimura R, Kato I, et al: Frequency of the hypercalcemia-leucocytosis syndrome in oral malignancies. Cancer 68:617, 1991
4. Geddes AD, D'Souza SM, Ebetino FH, et al: Bone and Mineral Research/8. New York, NY, Elsevier Science BV, 1994, p 265
5. Chapuy MC, Meunier PJ, Alexandre CM, et al: Effects of disodium dichloromethylene diphosphonates on hypercalcemia produced by bone metastases. J Clin Invest 65:1243, 1980
6. Coleman RE, Woll PJ, Miles M, et al: Treatment of bone metastases from breast cancer with (3-amino-1-hydroxyprolidene)-1,1-bisphosphonate (APD). Br J Cancer 58:621, 1988
7. Wimalawansa SJ: Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. Cancer 73:2223, 1994
8. Krempien B, Manegold C: Prophylactic treatment of skeletal metastases, tumor-induced osteolysis, and hypercalcemia in rats with the bisphosphonate C12MBP. Cancer 72:91, 1993
9. Sasaki A, Boyce BF, Story B, et al: Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 55:3551, 1995
10. Hall DG, Stoica G: Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system. J Bone Miner Res 9:221, 1994
11. Hiraga T, Tanaka S, Yamamoto M, et al: Inhibitory effects of bisphosphonate (YM175) on bone resorption induced by a metastatic bone tumor. Bone 18:1, 1996
12. Arguello F, Baggs RB, Frantz CN: A murine model of experimental metastasis to bone and bone marrow. Cancer Res 48:6876, 1988
13. Nakai M, Mundy GR, Williams PJ, et al: A synthetic antagonist to laminin inhibits the formation of osteolytic metastases by human melanoma cells in nude mouse. Cancer Res 52:5395, 1992
14. Hiraga T, Nakajima T, Ozawa H: Bone resorption induced by a metastatic human melanoma cell line. Bone 16:349, 1995
15. Martin TJ: Humoral hypercalcemia of malignancy. Bone Miner 4:83, 1988
16. Van De Wijngaert FP, Burger EH: Demonstration of tartrate-resistant acid phosphatase in undecalcified, glycolmethacrylate-embedded mouse bone: A possible marker for (pre)osteoclast identification. J Histochem Cytochem 34:1317, 1986
17. Tashjian AH, Wright DR, Ivey JL et al: Calcitonin binding sites in bone: Relationships to biological response and 'escape'. Rec Prog Horm Res 34:285, 1978
18. Heersche JNM: Calcitonin effects on osteoclastic resorption: The 'escape phenomenon' revisited. Bone Miner 16:174, 1992
19. Wisneski LA: Salmon calcitonin in the acute management of hypercalcemia. Calcif Tissue Int 46:S26, 1990
20. Takahashi S, Goldring S, Katz M, et al: Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J Clin Invest 95:167, 1995
21. Rakopoulos M, Ikegame M, Findlay DM, et al: Short treatment of osteoclasts in bone marrow culture with calcitonin causes prolonged suppression of calcitonin receptor mRNA. Bone 17:447, 1995
22. Marshall MJ: Effects of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate on mouse osteoclasts. J Bone Miner Res 5:955, 1990
23. Miller SC, Jee WSS: The effect of dichloromethylene diphosphonate, a pyrophosphate analog, on bone and bone cell structure in the growing rat. Anat Rec 193:439, 1979
24. Muhlbauer RC, Bauss F, Schenk R, et al: BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6:1003, 1991
25. Lowik CW, van der Pluijm G, van der Wee-Pals LJ, et al: Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: The effect of a bisphosphonate. J Bone Miner Res 3:185, 1988
26. Hughes DE, MacDonald BR, Russel RGG, et al: Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 83:1930, 1989
27. Marshall MJ, Holt I, Davie MWJ: Osteoclast recruitment in mice is stimulated by (3-amino-1-hydroxyprolidene)-1,1-bisphosphonate. Calcif Tissue Int 52:21, 1993
28. Kodama H, Yamasaki A, Niida S, et al: Transient recruitment of osteoclasts and expression of their function in osteopetrotic (op/op) mice by a single injection of macrophage colony-stimulating factor. J Bone Miner Res 8:45, 1993
29. Murakami H, Takahashi N, Sasaki T, et al: A possible mechanism of the specific action of bisphosphonates on osteoclasts: Tiludronate preferentially affects polarized osteclasts having ruffled borders. Bone 17:137, 1995